A new contract/technology adoption by Vizient can support incremental sales and strengthen BD’s competitive position in vascular access. However, it’s not clear from the article how large the financial impact will be, so near-term price impact is likely moderate.
BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System Maham Fatima Wed, July 1, 2026 at 10:16 AM GMT+2 2 min read BDX Becton, Dickinson & Company (NYSE: BDX ) is one of the best value stocks to buy right now . On June 23, BD (Becton, Dickinson & Company) announced that its CentroVena One Insertion System was awarded an Innovative Technology contract by Vizient, the nation's largest provider-driven healthcare performance improvement company. This contract recognizes the system as a breakthrough innovation that simplifies central line placement through an all-in-one design, potentially improving both patient outcomes and clinician safety.
The CentroVena One system integrates essential components (including the guidewire, needle, syringe, and catheter) into a single device. By streamlining the insertion process, it achieves 30% fewer procedural steps and can reduce maximum procedure time by up to 50% compared to standard techniques. These efficiencies also help mitigate risks such as contamination, needlestick injuries, and complications like air or guidewire embolisms.
BD (BDX) Receives Vizient Innovative Technology Contract for CentroVena One Insertion System Selected by hospital experts on Vizient's client-led councils, this contract validates the clear clinical need for a more standardized approach to central line insertion. By making this technology more accessible to Vizient's extensive network of healthcare providers, the agreement aims to drive meaningful improvements in procedural consistency, operational efficiency, and overall quality of care. Becton, Dickinson & Company (NYSE:BDX) is a global medical technology company headquartered in New Jersey.
The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. While we acknowledge the potential of BDX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .
READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy . Disclosure: None. Follow Insider Monkey on Google News .
Oraklio AI Trading Intelligence
Oraklio turns news, price data, and market signals into structured BUY / SELL / NO_TRADE calls - updated continuously throughout the trading day.
Get started freeAlready have an account? Sign in →